Drug intelligence / Profile preview

G-PERT

Development stage: Unknown
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

G-PERT is a generator-produced 99mTc Pertechnetate, a radiopharmaceutical used as a nuclear medicine test agent. It is approved by Health Canada for direct imaging and measurement of thyroid uptake, allowing for the creation of images of the thyroid gland and other organs. It is used in studies to compare its safety and imaging patterns with cyclotron-produced 99mTc Pertechnetate (CTC).

Other names: 99mTc Pertechnetate

Targets

NIS (Human sodium iodide symporter)

Beyond the preview

Go deeper on G-PERT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G-PERT.

Explore the full profile